Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their combination

Majewski, Sławomir; Szmurło, A.; Marczak, Maria; Jabłońska, Stefania; Bollag, W.

doi:10.1016/0304-3835(93)90204-m

Cited by 79 publications

(41 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 Moreover, several experimental studies have demonstrated the direct inhibitory effect of vitamin D3 on tumor-induced angiogenesis. [36][37][38] An adenoviral vector bearing a soluble Flk1 receptor has been reported to have the capacity to reduce tumor burden correlated with the degree of MVD in experimental animal models. 21,33,39 We have taken a mechanism-based approach to demonstrate for the first time the autocrine and paracrine effect of Ad-Flk1-Fc on tumor and tumor vasculature in vitro (Figures 2 and 3).…”

Section: Discussionmentioning

confidence: 99%

Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy

et al. 2004

View full text Add to dashboard Cite

Tumor-endothelial interaction contributes to local prostate tumor growth and distant metastasis. In this communication, we designed a novel approach to target both cancer cells and their ''crosstalk'' with surrounding microvascular endothelium in an experimental hormone refractory human prostate cancer model. We evaluated the in vitro and in vivo synergistic and/or additive effects of a combination of conditional oncolytic adenovirus plus an adenoviral-mediated antiangiogenic therapy. In the in vitro study, we demonstrated that human umbilical vein endothelial cells (HUVEC) and human C4-2 androgen-independent (AI) prostate cancer cells, when infected with an antiangiogenic adenoviral (Ad)-Flk1-Fc vector secreting a soluble form of Flk1, showed dramatically inhibited proliferation, migration and tubular formation of HUVEC endothelial cells. C4-2 cells showed maximal growth inhibition when coinfected with Ad-Flk1-Fc and Ad-hOC-E1, a conditional replication-competent Ad vector with viral replication driven by a human osteocalcin (hOC) promoter targeting both prostate cancer epithelial and stromal cells. Using a threedimensional (3D) coculture model, we found that targeting C4-2 cells with Ad-hOC-E1 markedly decreased tubular formation in HUVEC, as visualized by confocal microscopy. In a subcutaneous C4-2 tumor xenograft model, tumor volume was decreased by 40-60% in animals treated with Ad-Flk1-Fc or Ad-hOC-E1 plus vitamin D 3 alone and by 90% in a combined treatment group, compared to untreated animals in an 8-week treatment period. Moreover, three of 10 (30%) pre-established tumors completely regressed when animals received combination therapy. Cotargeting tumor and tumor endothelium could be a promising gene therapy strategy for the treatment of both localized and metastatic human prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy

et al. 2004

View full text Add to dashboard Cite

show abstract

“…In addition, it has a role in the control of cellular differentiation and proliferation (Bell, 1985;Reichel et al, 1989) and can promote cellular differentiation and inhibit proliferation of cancer in vitro (Colston et al, 1981;Frampton et al, 1983;Brehier and Thomasset, 1988) as well as inhibiting the invasive potential of human breast cancer cells in vitro (Hansen et al, 1994) and inhibiting tumour-induced angiogenesis (Majewski et al, 1993).…”

mentioning

confidence: 99%

A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer

et al. 2002

View full text Add to dashboard Cite

Inoperable cancer of the exocrine pancreas responds poorly to most conventional anti-cancer agents, and new agents are required to palliate this disease. Seocalcitol (EB1089), a vitamin D analogue, can inhibit growth, induce differentiation and induce apoptosis of cancer cell lines in vitro and can also inhibit growth of pancreatic cancer xenografts in vivo . Thirty-six patients with advanced pancreatic cancer received once daily oral treatment with seocalcitol with dose escalation every 2 weeks until hypercalcaemia occurred, following which patients continued with maintenance therapy. The most frequent toxicity was the anticipated dose-dependent hypercalcaemia, with most patients tolerating a dose of 10–15 μg per day in chronic administration. Fourteen patients completed at least 8 weeks of treatment and were evaluable for efficacy, whereas 22 patients were withdrawn prior to completing 8 weeks' treatment and in 20 of these patients withdrawal was due to clinical deterioration as a result of disease progression. No objective responses were observed, with five of 14 patients having stable disease in whom the duration of stable disease was 82–532 days (median=168 days). The time to treatment failure ( n =36) ranged from 22 to 847 days, and with a median survival of approximately 100 days. Seocalcitol is well tolerated in pancreatic cancer but has no objective anti-tumour activity in advanced disease. Further studies are necessary to determine if this agent has any cytostatic activity in this malignancy in minimal disease states. British Journal of Cancer (2002) 86 , 680–685. DOI: 10.1038/sj/bjc/6600162 www.bjcancer.com © 2002 Cancer Research UK

show abstract

“…1.25(OH),D, and its metabolites have also been shown to inhibit cell proliferation in human rectal mucosa (Thomas et al 1992). In addition I,25(OH),D, has been shown to inhibit tumour-induced angiogenesis (Majewski et al, 1993) and to inhibit the invasive potential of human breast cancer cells in vitro (Hansen et al 1994). Recently.…”

mentioning

confidence: 99%

A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer

Gulliford

J²,

Colston³

et al. 1998

Br J Cancer

142

View full text Add to dashboard Cite

Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their combination

Cited by 79 publications

References 15 publications

Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy

Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy

A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer

A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer

Contact Info

Product

Resources

About